{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:34:09Z","timestamp":1792794849084,"version":"4.5.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["REN-181678; CUG-171602; 950-232703"],"award-info":[{"award-number":["REN-181678; CUG-171602; 950-232703"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["REN-181678; CUG-171602; 950-232703"],"award-info":[{"award-number":["REN-181678; CUG-171602; 950-232703"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["REN-181678; CUG-171602; 950-232703"],"award-info":[{"award-number":["REN-181678; CUG-171602; 950-232703"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["REN-181678; CUG-171602; 950-232703"],"award-info":[{"award-number":["REN-181678; CUG-171602; 950-232703"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01328-3","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:09:47Z","timestamp":1762780187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Harnessing telemedicine to deliver patient-centered opioid agonist treatment within a community-based harm reduction service: a mixed methods evaluation"],"prefix":"10.1186","volume":"22","author":[{"given":"Stine Bordier","family":"H\u00f8j","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Coignard-Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aissata","family":"Sako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"de Montigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-\u00c8ve","family":"Beauchemin-Nadeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"L\u00e9andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanor","family":"Minoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Boyer-Legault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiane","family":"Chougar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara-Kim","family":"Lamont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bruneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"1328_CR1","first-page":"9241547545","volume-title":"Guidelines for the psychosocially assisted Pharmacological treatment of opioid dependence","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. Guidelines for the psychosocially assisted Pharmacological treatment of opioid dependence. Geneva, Switzerland: World Health Organization; 2009. p. 9241547545. Report No."},{"issue":"9","key":"1328_CR2","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","volume":"190","author":"J Bruneau","year":"2018","unstructured":"Bruneau J, Ahamad K, Goyer M-\u00c8, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: A National clinical practice guideline. Can Med Assoc J. 2018;190(9):E247\u201357.","journal-title":"Can Med Assoc J"},{"key":"1328_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","volume":"74","author":"KC Priest","year":"2019","unstructured":"Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing Canadian and united States opioid agonist therapy policies. Int J Drug Policy. 2019;74:257\u201365.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"1328_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/0706743717711167","volume":"62","author":"JK Eibl","year":"2017","unstructured":"Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after federal oversight. Can J Psychiatry Revue Canadienne De Psychiatrie. 2017;62(7):444\u201350.","journal-title":"Can J Psychiatry Revue Canadienne De Psychiatrie"},{"issue":"8","key":"1328_CR5","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/add.14947","volume":"115","author":"M Piske","year":"2020","unstructured":"Piske M, Zhou H, Min JE, Hongdilokkul N, Pearce LA, Homayra F, et al. The cascade of care for opioid use disorder: A retrospective study in British Columbia, Canada. Addiction. 2020;115(8):1482\u201393.","journal-title":"Addiction"},{"issue":"1","key":"1328_CR6","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12913-022-07877-8","volume":"22","author":"F Tahsin","year":"2022","unstructured":"Tahsin F, Morin KA, Vojtesek F, Marsh DC. Measuring treatment attrition at various stages of engagement in opioid agonist treatment in Ontario Canada using a cascade of care framework. BMC Health Serv Res. 2022;22(1):490.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"1328_CR7","doi-asserted-by":"publisher","first-page":"e0232086","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: A systematic review. PLoS ONE. 2020;15(5):e0232086.","journal-title":"PLoS ONE"},{"key":"1328_CR8","doi-asserted-by":"publisher","first-page":"100437","DOI":"10.1016\/j.lana.2023.100437","volume":"19","author":"B Fischer","year":"2023","unstructured":"Fischer B. The continuous opioid death crisis in canada: changing characteristics and implications for path options forward. Lancet Reg Health - Americas. 2023;19:100437.","journal-title":"Lancet Reg Health - Americas"},{"key":"1328_CR9","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"key":"1328_CR10","doi-asserted-by":"publisher","first-page":"108651","DOI":"10.1016\/j.drugalcdep.2021.108651","volume":"221","author":"NY Hall","year":"2021","unstructured":"Hall NY, Le L, Majmudar I, Mihalopoulos C. Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective. Drug Alcohol Depend. 2021;221:108651.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"1328_CR11","first-page":"316","volume":"28","author":"\u00c9 Lachapelle","year":"2021","unstructured":"Lachapelle \u00c9, Archambault L, Blouin C, Perreault M. Perspectives of people with opioid use disorder on improving addiction treatments and services. Drugs: Educ Prev Policy. 2021;28(4):316\u201327.","journal-title":"Drugs: Educ Prev Policy"},{"key":"1328_CR12","doi-asserted-by":"publisher","first-page":"m772","DOI":"10.1136\/bmj.m772","volume":"368","author":"LA Pearce","year":"2020","unstructured":"Pearce LA, Min JE, Piske M, Zhou H, Homayra F, Slaunwhite A, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020;368:m772.","journal-title":"BMJ"},{"issue":"1","key":"1328_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13722-021-00234-w","volume":"16","author":"L Mackay","year":"2021","unstructured":"Mackay L, Kerr T, Fairbairn N, Grant C, Milloy MJ, Hayashi K. The relationship between opioid agonist therapy satisfaction and Fentanyl exposure in a Canadian setting. Addict Sci Clin Pract. 2021;16(1):26.","journal-title":"Addict Sci Clin Pract"},{"issue":"7","key":"1328_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0277-9536(00)00098-8","volume":"51","author":"N Mead","year":"2000","unstructured":"Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 2000;51(7):1087\u2013110.","journal-title":"Soc Sci Med"},{"issue":"3","key":"1328_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.7812\/TPP\/12-025","volume":"16","author":"SM Greene","year":"2012","unstructured":"Greene SM, Tuzzio L, Cherkin D. A framework for making patient-centered care front and center. Permanente J. 2012;16(3):49.","journal-title":"Permanente J"},{"issue":"1","key":"1328_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2648.2012.06064.x","volume":"69","author":"A Kitson","year":"2012","unstructured":"Kitson A, Marshall A, Bassett K, Zeitz K. What are the core elements of patient-centred care? A narrative review and synthesis of the literature from health policy, medicine and nursing. J Adv Nurs. 2012;69(1):4\u201315.","journal-title":"J Adv Nurs"},{"issue":"9","key":"1328_CR17","doi-asserted-by":"publisher","first-page":"e107828","DOI":"10.1371\/journal.pone.0107828","volume":"9","author":"I Scholl","year":"2014","unstructured":"Scholl I, Zill JM, H\u00e4rter M, Dirmaier J. An integrative model of patient-centeredness \u2013 A systematic review and concept analysis. PLoS ONE. 2014;9(9):e107828.","journal-title":"PLoS ONE"},{"issue":"1","key":"1328_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13011-019-0227-0","volume":"14","author":"K Marchand","year":"2019","unstructured":"Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prev Policy. 2019;14(1):37.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"17","key":"1328_CR19","doi-asserted-by":"publisher","first-page":"E460","DOI":"10.1503\/cmaj.190430","volume":"191","author":"TD Brothers","year":"2019","unstructured":"Brothers TD, Bonn M. Patient-centred care in opioid agonist treatment could improve outcomes. Can Med Assoc J. 2019;191(17):E460\u20131.","journal-title":"Can Med Assoc J"},{"key":"1328_CR20","unstructured":"British Columbia Centre on Substance Use BMoH, and BC Ministry of Mental Health and Addictions. A guideline for the clinical management of opioid use disorder. Vancouver, BC: British Columbia Centre on Substance Use (BCCSU); 2023."},{"key":"1328_CR21","first-page":"1","volume-title":"Treating opioid use disorder in general medical settings","author":"DA Rastegar","year":"2021","unstructured":"Rastegar DA. Patient-Centered care in opioid use disorder treatment. In: Wakeman SE, Rich JD, editors. Treating opioid use disorder in general medical settings. Cham: Springer International Publishing; 2021. pp. 1\u20137."},{"issue":"3","key":"1328_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2012.08.002","volume":"24","author":"M Edland-Gryt","year":"2013","unstructured":"Edland-Gryt M, Skatvedt AH. Thresholds in a low-threshold setting: an empirical study of barriers in a centre for people with drug problems and mental health disorders. Int J Drug Policy. 2013;24(3):257\u201364.","journal-title":"Int J Drug Policy"},{"key":"1328_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"1328_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.socscimed.2013.01.031","volume":"83","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T, Martin A. Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting. Soc Sci Med. 2013;83:19\u201326.","journal-title":"Soc Sci Med"},{"key":"1328_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.drugpo.2015.08.018","volume":"27","author":"C Treloar","year":"2016","unstructured":"Treloar C, Rance J, Yates K, Mao L. Trust and people who inject drugs: the perspectives of clients and staff of needle syringe programs. Int J Drug Policy. 2016;27:138\u201345.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1328_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/14461242.2020.1789485","volume":"30","author":"A Farrugia","year":"2021","unstructured":"Farrugia A, Pienaar K, Fraser S, Edwards M, Madden A. Basic care as exceptional care: addiction stigma and consumer accounts of quality healthcare in Australia. Health Sociol Rev. 2021;30(2):95\u2013110.","journal-title":"Health Sociol Rev"},{"issue":"8","key":"1328_CR27","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/1467-9566.13180","volume":"42","author":"S Fraser","year":"2020","unstructured":"Fraser S, Moore D, Farrugia A, Edwards M, Madden A. Exclusion and hospitality: the subtle dynamics of stigma in healthcare access for people emerging from alcohol and other drug treatment. Sociol Health Illn. 2020;42(8):1801\u201320.","journal-title":"Sociol Health Illn"},{"issue":"1","key":"1328_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","volume":"17","author":"B Muncan","year":"2020","unstructured":"Muncan B, Walters SM, Ezell J, Ompad DC. They look at Us like junkies: influences of drug Use stigma on the healthcare engagement of people who inject drugs in new York City. Harm Reduct J. 2020;17(1):53.","journal-title":"Harm Reduct J"},{"key":"1328_CR29","doi-asserted-by":"publisher","first-page":"100295","DOI":"10.1016\/j.ssmqr.2023.100295","volume":"4","author":"M Addison","year":"2023","unstructured":"Addison M, Lhussier M, Bambra C. Relational stigma as a social determinant of health: i\u2019m not what you _____see me as. SSM - Qualitative Res Health. 2023;4:100295.","journal-title":"SSM - Qualitative Res Health"},{"issue":"1","key":"1328_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13722-021-00251-9","volume":"16","author":"K Marshall","year":"2021","unstructured":"Marshall K, Maina G, Sherstobitoff J. Plausibility of patient-centred care in high-intensity methadone treatment: reflections of providers and patients. Addict Sci Clin Pract. 2021;16(1):42.","journal-title":"Addict Sci Clin Pract"},{"issue":"Suppl 2","key":"1328_CR31","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1093\/cid\/cit263","volume":"57","author":"C Treloar","year":"2013","unstructured":"Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis. 2013;57(Suppl 2):S51\u20135.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1328_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/003335490411900109","volume":"119","author":"D Heller","year":"2004","unstructured":"Heller D, McCoy K, Cunningham C. An invisible barrier to integrating HIV primary care with harm reduction services: philosophical clashes between the harm reduction and medical models. Public Health Rep. 2004;119(1):32\u20139.","journal-title":"Public Health Rep"},{"key":"1328_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1891\/1541-6577.33.4.310","volume":"4","author":"D Denis-Lalonde","year":"2019","unstructured":"Denis-Lalonde D, Lind C, Estefan A. Beyond the buzzword: A concept analysis of harm reduction. Res Theory Nurs Pract. 2019;4:310\u201323.","journal-title":"Res Theory Nurs Pract"},{"issue":"4","key":"1328_CR34","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s11013-022-09807-z","volume":"47","author":"J Frankeberger","year":"2023","unstructured":"Frankeberger J, Gagnon K, Withers J, Hawk M. Harm reduction principles in a street medicine program: A qualitative study. Culture. Med Psychiatry. 2023;47(4):1005\u201321.","journal-title":"Med Psychiatry"},{"issue":"4","key":"1328_CR35","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/add.13214","volume":"111","author":"R McNeil","year":"2016","unstructured":"McNeil R, Kerr T, Pauly B, Wood E, Small W. Advancing patient-centered care for structurally vulnerable drug-using populations: A qualitative study of the perspectives of people who use drugs regarding the potential integration of harm reduction interventions into hospitals. Addiction. 2016;111(4):685\u201394.","journal-title":"Addiction"},{"key":"1328_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.socscimed.2014.01.051","volume":"106","author":"R McNeil","year":"2014","unstructured":"McNeil R, Small W. Safer environment interventions\u2019: A qualitative synthesis of the experiences and perceptions of people who inject drugs. Soc Sci Med. 2014;106:151\u20138.","journal-title":"Soc Sci Med"},{"issue":"1","key":"1328_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12954-022-00654-0","volume":"19","author":"A Jakubowski","year":"2022","unstructured":"Jakubowski A, Rath C, Harocopos A, Wright M, Welch A, Kattan J, et al. Implementation of buprenorphine services in NYC syringe services programs: A qualitative process evaluation. Harm Reduct J. 2022;19(1):75.","journal-title":"Harm Reduct J"},{"issue":"5\u20136","key":"1328_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/026327602761899246","volume":"19","author":"B Latour","year":"2002","unstructured":"Latour B, Venn C. Morality and Technology. Theory. Cult Soc. 2002;19(5\u20136):247\u201360.","journal-title":"Cult Soc"},{"key":"1328_CR39","doi-asserted-by":"publisher","first-page":"103875","DOI":"10.1016\/j.drugpo.2022.103875","volume":"110","author":"R Fomiatti","year":"2022","unstructured":"Fomiatti R, Shaw F, Fraser S. It\u2019s a different way to do medicine\u2019: exploring the affordances of telehealth for hepatitis C healthcare. Int J Drug Policy. 2022;110:103875.","journal-title":"Int J Drug Policy"},{"key":"1328_CR40","doi-asserted-by":"publisher","first-page":"e39236","DOI":"10.2196\/39236","volume":"9","author":"SB H\u00f8j","year":"2023","unstructured":"H\u00f8j SB, de Montigny C, Chougar S, L\u00e9andre R, Beauchemin-Nadeau M-\u00c8, Boyer-Legault G, et al. Co-constructing a community-based telemedicine program for people with opioid use disorder during the COVID-19 pandemic: lessons learned and implications for future service delivery. JMIR Public Health Surveillance. 2023;9:e39236.","journal-title":"JMIR Public Health Surveillance"},{"issue":"2","key":"1328_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7202\/1093863ar","volume":"55","author":"M Jauffret-Roustide","year":"2022","unstructured":"Jauffret-Roustide M, Bertrand K. COVID-19, usages de drogues et r\u00e9duction des risques: analyse crois\u00e9e des exp\u00e9riences et de l\u2019impact de La pand\u00e9mie En France et Au Qu\u00e9bec. Criminologie. 2022;55(2):17\u201342.","journal-title":"Criminologie"},{"issue":"1","key":"1328_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12954-022-00620-w","volume":"19","author":"N Minoyan","year":"2022","unstructured":"Minoyan N, H\u00f8j SB, Zolopa C, Vlad D, Bruneau J, Larney S. Self-reported impacts of the COVID-19 pandemic among people who use drugs: A rapid assessment study in Montreal, Canada. Harm Reduct J. 2022;19(1):38.","journal-title":"Harm Reduct J"},{"key":"1328_CR43","doi-asserted-by":"publisher","first-page":"103894","DOI":"10.1016\/j.drugpo.2022.103894","volume":"110","author":"C Zolopa","year":"2022","unstructured":"Zolopa C, Brothers TD, Leclerc P, Mary J-F, Morissette C, Bruneau J, et al. Changes in supervised consumption site use and emergency interventions in Montr\u00e9al, Canada in the first twelve months of the COVID-19 pandemic: an interrupted time series study. Int J Drug Policy. 2022;110:103894.","journal-title":"Int J Drug Policy"},{"key":"1328_CR44","doi-asserted-by":"publisher","first-page":"103237","DOI":"10.1016\/j.drugpo.2021.103237","volume":"93","author":"F Ali","year":"2021","unstructured":"Ali F, Russell C, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: A National qualitative assessment in Canada. Int J Drug Policy. 2021;93:103237.","journal-title":"Int J Drug Policy"},{"key":"1328_CR45","doi-asserted-by":"publisher","first-page":"108374","DOI":"10.1016\/j.jsat.2021.108374","volume":"129","author":"C Russell","year":"2021","unstructured":"Russell C, Ali F, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A National qualitative study. J Subst Abuse Treat. 2021;129:108374.","journal-title":"J Subst Abuse Treat"},{"key":"1328_CR46","doi-asserted-by":"crossref","unstructured":"Imtiaz S, Nafeh F, Russell C, Ali F, Elton-Marshall T, Rehm J. The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data. Substance Abuse Treat Prevent Policy. 2021;16(1):87.","DOI":"10.1186\/s13011-021-00423-5"},{"issue":"1","key":"1328_CR47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13722-021-00275-1","volume":"16","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Fawole A, Yang J, Tofighi B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Addict Sci Clin Pract. 2021;16(1):68.","journal-title":"Addict Sci Clin Pract"},{"key":"1328_CR48","doi-asserted-by":"publisher","first-page":"721898","DOI":"10.3389\/fdgth.2021.721898","volume":"3","author":"H Alami","year":"2021","unstructured":"Alami H, Lehoux P, Attieh R, Fortin J-P, Fleet R, Niang M, et al. A not so quiet revolution: systemic benefits and challenges of telehealth in the context of COVID-19 in Quebec (Canada). Front Digit Health. 2021;3:721898.","journal-title":"Front Digit Health"},{"key":"1328_CR49","doi-asserted-by":"publisher","first-page":"103742","DOI":"10.1016\/j.drugpo.2022.103742","volume":"106","author":"S Glegg","year":"2022","unstructured":"Glegg S, McCrae K, Kolla G, Touesnard N, Turnbull J, Brothers TD, et al. COVID just kind of opened a can of whoop-ass: the rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. Int J Drug Policy. 2022;106:103742.","journal-title":"Int J Drug Policy"},{"key":"1328_CR50","unstructured":"Letter from the Minister of Health regarding treatment and safer supply [press release]. Ottawa, ON: Government of Canada, 24 August 2020."},{"key":"1328_CR51","unstructured":"Brar R, Bruneau J, Butt P, Goyer M, Lim R, Poulin G, et al. Medications and other clinical approaches to support physical distancing for people who use substances during the COVID-19 pandemic: National rapid guidance document. Vancouver, BC: Canadian Research Initiative in Substance Misuse; 2020."},{"key":"1328_CR52","volume-title":"Telemedicine support for addiction services: National rapid guidance document","author":"J Bruneau","year":"2020","unstructured":"Bruneau J, Rehm J, Wild TC, Wood E, Sako A, Swansburg J, Lam A. Telemedicine support for addiction services: National rapid guidance document. Montreal, QC: Canadian Research Initiative in Substance Misuse; 2020."},{"key":"1328_CR53","unstructured":"Health Canada. Subsection 56(1) class exemption for patients, practitioners and pharmacists prescribing and providing controlled substances in Canada Ottawa, ON: Government of Canada. 2020. https:\/\/www.canada.ca\/en\/health-canada\/services\/health-concerns\/controlled-substances-precursor-chemicals\/policy-regulations\/policy-documents\/section-56-1-class-exemption-patients-pharmacists-practitioners-controlled-substances-covid-19-pandemic.html. Accessed 1 Nov 2021."},{"key":"1328_CR54","unstructured":"Goyer M-\u00c8, Hudon K, Plessis-B\u00e9lair M-C, Ferguson Y. Substance replacement therapy in the context of the COVID-19 pandemic in Qu\u00e9bec: clinical guidance for prescribers. Montreal, QC: Institut universitaire Sur les d\u00e9pendances (IUD); 2020. https:\/\/dependanceitinerance.ca\/app\/uploads\/2020\/10\/Guide-Pharmaco-COVID_ANG-VF.19.10.20.pdf. Accessed 10 Oct 2023."},{"key":"1328_CR55","unstructured":"Coll\u00e8ge des m\u00e9decins du Qu\u00e9bec. Trouble li\u00e9 \u00e0 l\u2019utilisation d\u2019opio\u00efdes (TUO): Prescription d\u2019un traitement par agonistes opio\u00efdes (TAO) durant la pand\u00e9mie Montreal, QC: Coll\u00e8ge des m\u00e9decins du Qu\u00e9bec. 2020. http:\/\/www.cmq.org\/page\/fr\/covid-19-trouble-lie-a-l-utilisation-d-opioides-tuo-prescription-d-un-traitement-par-agonistes-opioides-tao-durant-la-pandemie.aspx. Accessed 8 Apr 2020."},{"key":"1328_CR56","unstructured":"Coll\u00e8ge des m\u00e9decins du Qu\u00e9bec. Les t\u00e9l\u00e9consultations r\u00e9alis\u00e9es par les m\u00e9decins durant la pand\u00e9mie de COVID-19: Guide \u00e0 l\u2019intention des m\u00e9decins. Montreal, QC: Coll\u00e8ge des m\u00e9decins du Qu\u00e9bec; 31 March 2020. Accessed 11 May 2020."},{"key":"1328_CR57","unstructured":"Mignacca FG. Montreal\u2019s CACTUS safe-injecting community group sees more overdoses amid pandemic Montreal, QC: CBC News; 2020. Accessed 19 Jun 2024. https:\/\/www.cbc.ca\/news\/canada\/montreal\/cactus-montreal-opioid-overdoses-covid-19-1.5618901"},{"key":"1328_CR58","doi-asserted-by":"publisher","first-page":"109375","DOI":"10.1016\/j.drugalcdep.2022.109375","volume":"233","author":"B Nosyk","year":"2022","unstructured":"Nosyk B, Min JE, Pearce LA, Zhou H, Homayra F, Wang L, et al. Development and validation of health system performance measures for opioid use disorder in British Columbia, Canada. Drug Alcohol Depend. 2022;233:109375.","journal-title":"Drug Alcohol Depend"},{"key":"1328_CR59","doi-asserted-by":"publisher","first-page":"108647","DOI":"10.1016\/j.jsat.2021.108647","volume":"133","author":"M Kurz","year":"2022","unstructured":"Kurz M, Min JE, Dale LM, Nosyk B. Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada. J Subst Abuse Treat. 2022;133:108647.","journal-title":"J Subst Abuse Treat"},{"key":"1328_CR60","doi-asserted-by":"publisher","first-page":"108799","DOI":"10.1016\/j.drugalcdep.2021.108799","volume":"225","author":"E Krebs","year":"2021","unstructured":"Krebs E, Homayra F, Min JE, MacDonald S, Gold L, Carter C, Nosyk B. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012\u20132018. Drug Alcohol Depend. 2021;225:108799.","journal-title":"Drug Alcohol Depend"},{"key":"1328_CR61","doi-asserted-by":"crossref","unstructured":"Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf. 2016;25(6):733\u20137.","DOI":"10.1002\/pds.3945"},{"key":"1328_CR62","doi-asserted-by":"publisher","first-page":"116718","DOI":"10.1016\/j.jns.2020.116718","volume":"411","author":"DA Patterson Silver Wolf","year":"2020","unstructured":"Patterson Silver Wolf DA, Gold M. Treatment resistant opioid use disorder (TROUD): Definition, rationale, and recommendations. J Neurol Sci. 2020;411:116718.","journal-title":"J Neurol Sci"},{"issue":"8","key":"1328_CR63","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1007\/s11606-020-05920-0","volume":"35","author":"S Kimmel","year":"2020","unstructured":"Kimmel S, Bach P, Walley AY. Comparison of treatment options for refractory opioid use disorder in the united States and canada: A narrative review. J Gen Intern Med. 2020;35(8):2418\u201326.","journal-title":"J Gen Intern Med"},{"key":"1328_CR64","doi-asserted-by":"crossref","unstructured":"Voon P, Joe R, Fairgrieve C, Ahamad K. Treatment of opioid use disorder in an innovative community-based setting after multiple treatment attempts in a woman with untreated HIV. BMJ Case Rep. 2016;2016:bcr2016215557.","DOI":"10.1136\/bcr-2016-215557"},{"issue":"1","key":"1328_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pec.2018.08.029","volume":"102","author":"J H\u00e5kansson Eklund","year":"2019","unstructured":"H\u00e5kansson Eklund J, Holmstr\u00f6m IK, Kumlin T, Kaminsky E, Skoglund K, H\u00f6glander J, et al. Same same or different? A review of reviews of person-centered and patient-centered care. Patient Educ Couns. 2019;102(1):3\u201311.","journal-title":"Patient Educ Couns"},{"issue":"1","key":"1328_CR66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/02791072.2001.10400463","volume":"33","author":"GA Marlatt","year":"2001","unstructured":"Marlatt GA, Blume AW, Parks GA. Integrating harm reduction therapy and traditional substance abuse treatment. J Psychoactive Drugs. 2001;33(1):13\u201321.","journal-title":"J Psychoactive Drugs"},{"issue":"3","key":"1328_CR67","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3122\/jabfm.2022.220303R3","volume":"36","author":"JE Chang","year":"2023","unstructured":"Chang JE, Lindenfeld Z, Hagan H. Integrating harm reduction into medical care: lessons from three models. J Am Board Fam Med. 2023;36(3):449\u201361.","journal-title":"J Am Board Fam Med"},{"issue":"4","key":"1328_CR68","doi-asserted-by":"publisher","first-page":"215824401350925","DOI":"10.1177\/2158244013509252","volume":"3","author":"G Salvalaggio","year":"2013","unstructured":"Salvalaggio G, McKim R, Taylor M, Wild TC. Patient\u2013provider rapport in the health care of people who inject drugs. SAGE Open. 2013;3(4):2158244013509252.","journal-title":"SAGE Open"},{"issue":"2","key":"1328_CR69","first-page":"163","volume":"7","author":"R Lilly","year":"2000","unstructured":"Lilly R, Quirk A, Rhodes T, Stimson GV. Sociality in methadone treatment: Understanding methadone treatment and service delivery as a social process. Drugs: Educ Prev Policy. 2000;7(2):163\u201378.","journal-title":"Drugs: Educ Prev Policy"},{"issue":"4","key":"1328_CR70","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/1468-0009.00223","volume":"79","author":"MA Hall","year":"2001","unstructured":"Hall MA, Dugan E, Zheng B, Mishra AK. Trust in physicians and medical institutions: what is it, can it be measured, and does it matter? Milbank Q. 2001;79(4):613\u201339.","journal-title":"Milbank Q"},{"issue":"2","key":"1328_CR71","doi-asserted-by":"publisher","first-page":"e080790","DOI":"10.1136\/bmjopen-2023-080790","volume":"14","author":"KA Morin","year":"2024","unstructured":"Morin KA, Tatangelo M, Marsh D. Canadian addiction treatment centre (CATC) opioid agonist treatment cohort in Ontario, Canada. BMJ Open. 2024;14(2):e080790.","journal-title":"BMJ Open"},{"key":"1328_CR72","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.drugpo.2016.09.003","volume":"39","author":"M Vogel","year":"2017","unstructured":"Vogel M, D\u00fcrsteler KM, Walter M, Herdener M, Nordt C. Rethinking retention in treatment of opioid dependence: the eye of the beholder. Int J Drug Policy. 2017;39:109\u201313.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"1328_CR73","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with All-Cause mortality and specific causes of death among people with opioid dependence: A systematic review and Meta-analysis. JAMA Psychiatry. 2021;78(9):979\u201393.","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"1328_CR74","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/aje\/kwp186","volume":"170","author":"B Nosyk","year":"2009","unstructured":"Nosyk B, MacNab YC, Sun H, Fischer B, Marsh DC, Schechter MT, Anis AH. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol. 2009;170(6):783\u201392.","journal-title":"Am J Epidemiol"},{"key":"1328_CR75","doi-asserted-by":"publisher","first-page":"103773","DOI":"10.1016\/j.drugpo.2022.103773","volume":"107","author":"A Pilarinos","year":"2022","unstructured":"Pilarinos A, Kwa Y, Joe R, Thulien M, Buxton JA, DeBeck K, Fast D. Navigating opioid agonist therapy among young people who use illicit opioids in Vancouver, Canada. Int J Drug Policy. 2022;107:103773.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1328_CR76","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drugalcdep.2005.05.010","volume":"81","author":"J Bell","year":"2006","unstructured":"Bell J, Burrell T, Indig D, Gilmour S. Cycling in and out of treatment: participation in methadone treatment in NSW, 1990\u20132002. Drug Alcohol Depend. 2006;81(1):55\u201361.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1328_CR77","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/add.14442","volume":"114","author":"C Nordt","year":"2019","unstructured":"Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T, et al. One size does not fit all\u2014evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction. 2019;114(1):103\u201311.","journal-title":"Addiction"},{"key":"1328_CR78","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.drugalcdep.2018.02.018","volume":"187","author":"AE Muller","year":"2018","unstructured":"Muller AE, Bj\u00f8rnestad R, Clausen T. Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications. Drug Alcohol Depend. 2018;187:22\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"1328_CR79","doi-asserted-by":"publisher","first-page":"104023","DOI":"10.1016\/j.drugpo.2023.104023","volume":"115","author":"K Giang","year":"2023","unstructured":"Giang K, Charlesworth R, Thulien M, Mulholland A, Barker B, Brar R, et al. Risk mitigation guidance and safer supply prescribing among young people who use drugs in the context of COVID-19 and overdose emergencies. Int J Drug Policy. 2023;115:104023.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"1328_CR80","doi-asserted-by":"publisher","first-page":"e2411389","DOI":"10.1001\/jamanetworkopen.2024.11389","volume":"7","author":"JE Min","year":"2024","unstructured":"Min JE, Guerra-Alejos BC, Yan R, Palis H, Barker B, Urbanoski K, et al. Opioid coprescription through risk mitigation guidance and opioid agonist treatment receipt. JAMA Netw Open. 2024;7(5):e2411389\u2013e.","journal-title":"JAMA Netw Open"},{"key":"1328_CR81","doi-asserted-by":"crossref","unstructured":"Sanders JJ, Roose RJ, Lubrano MC, Lucan SC. Meaning and methadone: patient perceptions of methadone dose and a model to promote adherence to maintenance treatment. J Addict Med. 2013;7(5):307\u201313.","DOI":"10.1097\/ADM.0b013e318297021e"},{"issue":"25","key":"1328_CR82","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.2174\/13816128113199990623","volume":"20","author":"P Roux","year":"2014","unstructured":"Roux P, Lions C, Michel L, Cohen J, Mora M, Marcellin F, et al. Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians. Curr Pharm Design. 2014;20(25):4097\u2013105.","journal-title":"Curr Pharm Design"},{"issue":"17","key":"1328_CR83","doi-asserted-by":"publisher","first-page":"E462","DOI":"10.1503\/cmaj.181506","volume":"191","author":"AA Artenie","year":"2019","unstructured":"Artenie AA, Minoyan N, Jacka B, H\u00f8j S, Jutras-Aswad D, Roy \u00c9, et al. Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs. Can Med Assoc J. 2019;191(17):E462\u20138.","journal-title":"Can Med Assoc J"},{"issue":"4","key":"1328_CR84","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jsat.2014.05.012","volume":"47","author":"R H\u00e4mmig","year":"2014","unstructured":"H\u00e4mmig R, K\u00f6hler W, Bonorden-Kleij K, Weber B, Lebentrau K, Berthel T, et al. Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. J Subst Abuse Treat. 2014;47(4):275\u201381.","journal-title":"J Subst Abuse Treat"},{"issue":"11","key":"1328_CR85","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/j.1360-0443.2008.02334.x","volume":"103","author":"A Kastelic","year":"2008","unstructured":"Kastelic A, Dubajic G, Strbad E. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction. 2008;103(11):1837\u201346.","journal-title":"Addiction"},{"key":"1328_CR86","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","volume":"160","author":"BJH Yarborough","year":"2016","unstructured":"Yarborough BJH, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. Drug Alcohol Depend. 2016;160:112\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"1328_CR87","doi-asserted-by":"publisher","first-page":"109932","DOI":"10.1016\/j.drugalcdep.2023.109932","volume":"248","author":"V Mocanu","year":"2023","unstructured":"Mocanu V, Bozinoff N, Wood E, Jutras-Aswad D, Le Foll B, Lim R, et al. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: secondary analysis of a pragmatic randomized trial. Drug Alcohol Depend. 2023;248:109932.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1328_CR88","doi-asserted-by":"publisher","first-page":"e2411398","DOI":"10.1001\/jamanetworkopen.2024.11398","volume":"7","author":"AJ Saxon","year":"2024","unstructured":"Saxon AJ. Short-acting, full agonist opioids during initiation of opioid agonist treatment in the Fentanyl era. JAMA Netw Open. 2024;7(5):e2411398\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"1328_CR89","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/bjsw\/bcm053","volume":"38","author":"B Behnia","year":"2007","unstructured":"Behnia B. Trust development: A discussion of three approaches and a proposed alternative. Br J Social Work. 2007;38(7):1425\u201341.","journal-title":"Br J Social Work"},{"issue":"1","key":"1328_CR90","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1525\/si.1992.15.1.87","volume":"15","author":"GA Fine","year":"1992","unstructured":"Fine GA. Agency, structure, and comparative contexts: toward a synthetic interactionism. Symbolic Interact. 1992;15(1):87\u2013107.","journal-title":"Symbolic Interact"},{"issue":"2","key":"1328_CR91","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.socscimed.2011.10.003","volume":"74","author":"J Rance","year":"2012","unstructured":"Rance J, Newland J, Hopwood M, Treloar C. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics. Soc Sci Med. 2012;74(2):245\u201353.","journal-title":"Soc Sci Med"},{"issue":"6","key":"1328_CR92","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1177\/1049732311432718","volume":"22","author":"J Harris","year":"2012","unstructured":"Harris J, McElrath K. Methadone as social control: institutionalized stigma and the prospect of recovery. Qual Health Res. 2012;22(6):810\u201324.","journal-title":"Qual Health Res"},{"issue":"10","key":"1328_CR93","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.drugpo.2015.05.005","volume":"26","author":"M Harris","year":"2015","unstructured":"Harris M, Albers E, Swan T. The promise of treatment as prevention for hepatitis C: meeting the needs of people who inject drugs? Int J Drug Policy. 2015;26(10):963\u20139.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"1328_CR94","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/1475-6773.01070","volume":"37","author":"MA Hall","year":"2002","unstructured":"Hall MA, Camacho F, Dugan E, Balkrishnan R. Trust in the medical profession: conceptual and measurement issues. Health Serv Res. 2002;37(5):1419\u201339.","journal-title":"Health Serv Res"},{"key":"1328_CR95","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1017\/S0950268823000675","volume":"151","author":"PTZ Aung","year":"2023","unstructured":"Aung PTZ, Spelman T, Wilkinson AL, Dietze PM, Stoov\u00e9 MA, Hellard ME. Time-to-hepatitis C treatment initiation among people who inject drugs in Melbourne, Australia. Epidemiol Infect. 2023;151:e84.","journal-title":"Epidemiol Infect"},{"key":"1328_CR96","doi-asserted-by":"publisher","first-page":"103954","DOI":"10.1016\/j.drugpo.2023.103954","volume":"113","author":"N Jiang","year":"2023","unstructured":"Jiang N, Bruneau J, Makarenko I, Minoyan N, Zang G, H\u00f8j SB, et al. HCV treatment initiation in the era of universal direct acting antiviral coverage - Improvements in access and persistent barriers. Int J Drug Policy. 2023;113:103954.","journal-title":"Int J Drug Policy"},{"key":"1328_CR97","doi-asserted-by":"publisher","first-page":"104044","DOI":"10.1016\/j.drugpo.2023.104044","volume":"116","author":"KB Malme","year":"2023","unstructured":"Malme KB, Ulstein K, Finbr\u00e5ten A-K, W\u00fcsthoff LEC, Kielland KB, Hauge J, et al. Hepatitis C treatment uptake among people who inject drugs in Oslo, norway: A registry-based study. Int J Drug Policy. 2023;116:104044.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1328_CR98","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12954-025-01166-3","volume":"22","author":"Z Papalamprakopoulou","year":"2025","unstructured":"Papalamprakopoulou Z, Ntagianta E, Triantafyllou V, Kalamitsis G, Dharia A, Dickerson SS, et al. Breaking the vicious cycle of delayed healthcare seeking for people who use drugs. Harm Reduct J. 2025;22(1):27.","journal-title":"Harm Reduct J"},{"issue":"3","key":"1328_CR99","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/08897077.2020.1787300","volume":"41","author":"G Cochran","year":"2020","unstructured":"Cochran G, Bruneau J, Cox N, Gordon AJ. Medication treatment for opioid use disorder and community pharmacy: expanding care during a National epidemic and global pandemic. Subst Abus. 2020;41(3):269\u201374.","journal-title":"Subst Abus"},{"key":"1328_CR100","doi-asserted-by":"crossref","unstructured":"Fatani S, Bakke D, D\u2019Eon M, El-Aneed A. Qualitative assessment of patients\u2019 perspectives and needs from community pharmacists in substance use disorder management. Subst Abuse Treat Prevent Policy. 2021;16(1):38.","DOI":"10.1186\/s13011-021-00374-x"},{"key":"1328_CR101","doi-asserted-by":"publisher","first-page":"109303","DOI":"10.1016\/j.drugalcdep.2022.109303","volume":"232","author":"LD Bishop","year":"2022","unstructured":"Bishop LD, Rosenberg-Yunger ZRS. Pharmacists expanded role in providing care for opioid use disorder during COVID-19: A qualitative study exploring pharmacists\u2019 experiences. Drug Alcohol Depend. 2022;232:109303.","journal-title":"Drug Alcohol Depend"},{"key":"1328_CR102","doi-asserted-by":"crossref","unstructured":"Tyndall M. Safer opioid distribution in response to the COVID-19 pandemic. Int J Drug Policy. 2020;83:102880.","DOI":"10.1016\/j.drugpo.2020.102880"},{"key":"1328_CR103","doi-asserted-by":"publisher","first-page":"116683","DOI":"10.1016\/j.socscimed.2024.116683","volume":"345","author":"G Bardwell","year":"2024","unstructured":"Bardwell G, Ivsins A, Wallace JR, Mansoor M, Kerr T. The machine doesn\u2019t judge: counternarratives on surveillance among people accessing a safer opioid supply via biometric machines. Soc Sci Med. 2024;345:116683.","journal-title":"Soc Sci Med"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01328-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:07:06Z","timestamp":1762884426000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01328-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1328"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01328-3","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM) research ethics board. All participants signed an informed consent to participate in the study. The analysis plan was not pre-registered and results should be considered exploratory.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JB reports a relationship with Gilead Sciences that includes: consulting or advisory and funding grants and a relationship with AbbVie that includes: consulting or advisory, outside the scope of this manuscript. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}